The weaker backdrop means the FTSE 100 index is forecast to give up all yesterday’s rise, with futures pointing to a decline ...

Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50 ... corporate insider sentiment is positive on ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

JPMorgan lowered the firm’s price target on GSK (GSK) to 1,440 GBp from 1,550 GBp and keeps an Underweight rating on the shares. TipRanks is the most comprehensive data set of sell side analysts ...

The firm has removed its price target for GSK, previously set to guide investors on the stock's potential value. The downgrade reflects concerns about the limited upside in the company's pipeline ...